Ryan E Anson

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Peptide vaccination against tumor-associated antigens remains one of the most common methods of immunization in cancer vaccine clinical trials. Although peptide vaccination has been reported to increase circulating antigen-specific T-cells, they have had limited clinical efficacy and there is a necessity to increase their capacity to generate strong(More)
  • 1